Ποια είναι η τιμή για Citius Pharmaceuticals, Inc. (CTXR)

Η τιμή για Citius Pharmaceuticals, Inc. (CTXR) είναι $0.5762

Ποια είναι η κεφαλαιοποίηση αγοράς για Citius Pharmaceuticals, Inc. (CTXR)

Η κεφαλαιοποίηση αγοράς για Citius Pharmaceuticals, Inc. (CTXR) είναι $6.44M

Citius Pharmaceuticals, Inc. (CTXR) Τιμή και Κεφαλαιοποίηση Αγοράς

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Η τιμή για CTXR	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$488,625 $6.44M	NVDA	$5.460T	+84,801,181.02%
$401,762 $6.44M	AAPL	$4.489T	+69,725,953.50%
$370,566 $6.44M	GOOG	$4.141T	+64,311,967.86%
$319,346 $6.44M	MSFT	$3.569T	+55,422,699.46%
$250,394 $6.44M	AMZN	$2.798T	+43,456,015.37%

Η τιμή για CTXR

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$488,625 $6.44M